Topics

Gilead and Galapagos' JAK Inhibitor Stumbles in Mid-Stage Lupus Trial

20:00 EDT 27 Oct 2019 | BioSpace

Despite the success Gilead Sciences has seen with its JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren's syndrome.

Original Article: Gilead and Galapagos' JAK Inhibitor Stumbles in Mid-Stage Lupus Trial

NEXT ARTICLE

More From BioPortfolio on "Gilead and Galapagos' JAK Inhibitor Stumbles in Mid-Stage Lupus Trial"

Quick Search

Relevant Topics

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...